Brief: Io Biotech-On Feb 15 Filed New Prospectus Supplement With U.S. SEC With Respect To Offer & Sale Of Shares Of Common Stock, Par Value $0.001 Per Share
Brief: Io Biotech Inc Files For Mixed Shelf Offering Of Up To $250 Million
Brief: IO Biotech Announces Appointment Of Devin Smith As General Counsel
Brief: Io Biotech Provides Business Update
Brief: Io Biotech Announces Third Quarter Results For 2022
IO Biotech gains on agreement with Merck for cancer therapy trial
Brief: IO Biotech Appointments Amy Sullivan As CFO
Brief: IO Biotech Announces Second Quarter Results For 2022
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:11 AM
Brief: Io Biotech Announces Two Presentations At The American Society Of Clinical Oncology Annual Meeting 2022
Brief: IO Biotech Announces Initiation Of Phase 3 Combination Trial Of IO102-IO103 And Keytruda
Brief: IO Biotech Announces First Quarter Results For 2022
Brief: IO Biotech, CFO Terminate Employment By Mutual Agreement
Brief: IO Biotech Initiates Trial of IO102-IO103 in Combination With KEYTRUDA as First-Line Treatment in Multi-Arm Basket Trial
Brief: IO Biotech Announces Presentation Of New Data From MM1636 Phase 1/2 Clinical Trial Presented At 2022 AACR Annual Meeting
Brief: Io Biotech Announces Year-End Results For 2021
Brief: Io Biotech Announces Publication Of Phase 1/2 Melanoma Clinical Trial Results In Nature Medicine
Brief: IO Biotech Announces Third Clinical Collaboration With Merck To Evaluate IO102-IO103 in Combination With KEYTRUDA
NASDAQ RESUMED AT 09:45 AM